quality adjusted life year

quality adjusted life year

A parameter derived from a modification of standard life-table procedures, which is designed to take account of the quality of life as well as the duration of survival with a particular disease—e.g., cancer, diabetes, multiple sclerosis. QALY can also be used in assessing the outcome of healthcare procedures or services.
References in periodicals archive ?
One Quality Adjusted Life Year is equal to one year of perfect health.
But a preliminary appraisal by the New Medicines Group issued to AWMSG says the case for cost-effectiveness for the drug "has not been proven" and estimates the cost to be more than PS500,000 per quality adjusted life year - a measurement which looks at both the quality and the quantity of life added by a drug.
Researchers used the Quality Adjusted Life Year (QALY) scale to measure benefit to patients in comparison to the direct and indirect costs of the surgical procedures over a two-year period after surgery.
As to establishing the value of a drug under the proposed scheme, the OFT advocates the Quality Adjusted Life Year ('QALY') measure used by the National Institute of Clinical Excellence ('NICE').
Even if the prevalence were as low as 5/10,000, the cost per quality adjusted life year would still be under $50,000.
Set against the Quality Adjusted Life Year scale, which measures 'life gains', it works out about pounds 19,000 but compared to the cost of prescribing antibiotics for meningitis, it's still an expensive option.
The findings showed a $33,025 (USD) cost per Quality Adjusted Life Year (QALY) gained using Medtronic CRT-Ds in a mild, New York Heart Association (NYHA)-designated Class II-III heart failure patient population, substantially lower than the benchmark for therapy cost effectiveness of other serious chronic conditions that cost at least $50,000 per QALY gained.
htm 2 Quality adjusted life year refers to units of measure of utility which combine life years gained as a result of health interventions/health care programs with a judgment about the quality of these life years.
The results demonstrate that the incremental cost-effectiveness is EUR 7,614 (GBP 5,128/$9,798) for CRT and EUR 18,199 (GBP 12,257/$23,419) for CRT-D when compared with optimal medical therapy per quality adjusted life year (QALY), which is substantially lower than the threshold of EUR 44,542 (GBP 30,000/$57,305) per QALY estimate that is widely considered to be acceptable value for cost effectiveness.
24 quality adjusted life years with an incremental cost effectiveness ratio of $88,700 per quality adjusted life year when compared to the MTWA risk stratification strategy.
Compared to optimal medical therapy, CRT is shown to be highly cost-effective at $6,131 per quality adjusted life year (QALY).
The results of the simulations revealed an Incremental Cost Effectiveness Ratio (ICER) of $88,700 per Quality Adjusted Life Year (QALY) in the ICDs FOR ALL strategy as compared to the use of MTWA risk stratification.

Full browser ?